Differential effects of heart rate reduction by atenolol or ivabradine on peripheral endothelial function in type 2 diabetic patients

Roberto Nerla, Antonino Di Franco, Maria Milo, Dario Pitocco, Francesco Zaccardi, Pierpaolo Tarzia, Filippo Maria Sarullo, Angelo Villano, Giulio Russo, Alessandra Stazi, Giovanni Ghirlanda, Gaetano Antonio Lanza, Filippo Crea

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: To assess whether reduction of heart rate (HR) has beneficial effects on endothelial function in patients with type 2 diabetes mellitus (T2DM). Design: Randomised, double-blind, placebo-controlled study. Setting: University hospital. Patients: 66 T2DM patients without overt cardiovascular disease. Interventions: Patients were randomised to receive for 4 weeks, in addition to their standard therapy, one of the following treatments: atenolol (25 mg twice daily), ivabradine (5 mg twice daily) or placebo (1 tablet twice daily). Main outcome measures: Systemic endothelial function, assessed by flow-mediated dilation (FMD); endothelium-independent vasodilation, assessed by nitrate-mediated dilation (NMD); cardiac autonomic function, assessed by HR variability (HRV). Results: 61 patients completed the study (19, 22 and 20 patients in atenolol, ivabradine and placebo groups, respectively). Compared with baseline, HR was similarly reduced by atenolol (87±13 vs 69±9 bpm) and ivabradine (86±12 to 71±9 bpm), but not by placebo (82±10 vs 81±9 bpm) (p

Original languageEnglish
Pages (from-to)1812-1816
Number of pages5
JournalHeart
Volume98
Issue number24
DOIs
Publication statusPublished - Dec 2012

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Differential effects of heart rate reduction by atenolol or ivabradine on peripheral endothelial function in type 2 diabetic patients'. Together they form a unique fingerprint.

Cite this